Altimmune Cost Of Revenue Over Time

ALT Stock  USD 8.25  0.07  0.86%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Altimmune Performance and Altimmune Correlation.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
  
Cost Of Revenue is likely to drop to about 453.1 K in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.57)
Revenue Per Share
0.001
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.40)
Return On Equity
(0.73)
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Cost Of Revenue Analysis

Compare Altimmune and related stocks such as Reviva Pharmaceuticals, Athira Pharma, and Fortress Biotech Cost Of Revenue Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ATHAMMMMMMMMMMM479 KM969 K899.2 K
FBIO0.00.00.00.00.051.4 M11.3 M161.2 M6.1 M10.5 M14.6 M32.1 M30.8 M26.7 M29.2 M
ACAD17.6 M23.5 M25.7 M26.7 M93.1 M2.5 M4.4 M13.1 M18.3 M19.6 M20.6 M19.1 M10.2 M45.7 M25.4 M
CABA104 K104 K104 K104 K104 K104 K104 K104 K104 K104 K354 K733 K3.7 M1.4 M1.4 M
AKRO0.00.00.00.00.00.00.00.00.080.2 M80.2 M100.9 M260 K29 K27.6 K
TERN65 K65 K65 K65 K65 K65 K65 K65 K65 K195 K394 K512 KM881 K564.5 K
MDGL0.00.00.00.00.00.015677 K96 K112 K471 K405 K467 K527 K553.4 K
INZY83 K83 K83 K83 K83 K83 K83 K83 K83 K83 K217 K1.1 M1.2 M1.3 M841.1 K
AVXLK12 K12 K0.00.00.00.00.00.00.00.00.00.00.00.0
SAVA(1.5 M)7.6 K7.6 K4.9 K7.3 K9.1 M9.2 M7.6 MM1.6 M346 K534 K1.3 M89.4 M93.9 M
INMB0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
BIVI0.00.00.00.00.00.00.00.0229.4 K229.4 K229.4 K237.4 K266.8 K229.4 K142.2 K
CGTX81 K81 K81 K81 K81 K81 K81 K81 K81 K81 K98 K93 K235 K252 K167 K
ARDX13.5 M13.5 M13.5 M31.2 M32.9 M1.3 M0.08.4 M466 K600 K145 K1000 K4.1 M17.8 M18.7 M
HEPA26.7 K26.7 K26.7 K26.7 K26.7 K26.7 K26.7 K26.7 K26.7 K26.7 K34.5 K86.1 K77.5 K67.1 K64.2 K
VSTM0.00.00.00.00.00.00.00.0165 K2.8 M33.7 M206 K118 K62 K58.9 K
XFOR0.00.00.00.00.00.00.00.00.0672 K1.9 M1.9 MMMM
DAWN155 K155 K155 K155 K155 K155 K155 K155 K155 K155 K155 K199 K531 K383 K348.7 K
HOOK9.8 M9.8 M9.8 M9.8 M9.8 M9.8 M9.8 M9.8 M22 M46.3 M53.1 M4.6 M3.6 M3.6 M3.4 M

Altimmune and related stocks such as Reviva Pharmaceuticals, Athira Pharma, and Fortress Biotech Cost Of Revenue description

Cost of Revenue is found on Altimmune income statement and represents the costs associated with goods and services Altimmune provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

My Equities

My Current Equities and Potential Positions

Altimmune
ALT
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMaryland; U.S.A
ExchangeNASDAQ Exchange
USD 8.25

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.